Back

AnaCardio raises €62.5 million to advance AC01 heart-failure therapy

Verifying
  • AnaCardio completed a €62.5 million Series B financing for AC01 development.
  • AC01 increased cardiac output 22% and ejection fraction 4.8 percentage points after 28 days.
  • GOAL-HF2 is expected to enroll its first participant in Q4 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.